Search for content, post, videos

Small Cap Stocks Alert – NeoPhotonics Corp (NPTN), Synergy Pharmaceuticals Inc (SGYP), Ambarella Inc (AMBA)

NeoPhotonics Corp (NYSE:NPTN) percentage change gained +10.42% to close at $10.81 with the total traded volume of 742,606.00 shares less than average volume of 529,636.00.

Its beta value stands at 0.56 times and earning per share was $0.13. The company has total of 40.52M outstanding shares and its total market capitalization is $396.72M.

52-week price range of the stock remained $2.75 – $11.19, while during last trade its minimum price was $9.83 and it gained highest price of $10.88. NeoPhotonics Corp (NYSE:NPTN) designs and manufactures hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks. Its products include transmitter, receiver, and switching products for 100 gigabits per second (Gbps) optical transmission applications over distances of 2 to 2,000 kilometers; a range of products for optical communications networks and other applications, where the networks operate at speeds less than 100Gbps; and optical components for coherent systems, which manipulate light to encode ten times or more the amount of information in the same wavelength channel than is possible with traditional methods.

Can NPTN Show a Strong Recovery? Find out in This Research Report

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) remained among the day gainers and traded with volume of 742,034.00 shares in the last session as compared to average volume of 1.50M shares.

52 week range of the stock remained $2.75 – $10.15, while its day lowest price was $5.68 and its hit its day highest price at $5.84. SGYP total market capitalization is $658.17M along with 113.67M shares outstanding. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

Get a Free Report and Detailed Analysis on SGYP Click Here to Read

Ambarella Inc (NASDAQ:AMBA) started its trading session with the price $59.54, and closed at price of $58.58 by scoring -1.76%.

APC stock traded with total volume of 738,528.00 shares while the average trading capacity remained 2.34M shares. The beta of the APC stands at 1.30. Day range of the stock was $58.15 – $60.09. Ambarella Inc (NASDAQ:AMBA) publicized on 11 December that the Global Semiconductor Alliance (GSA) of Santa Clara, California has honored Ambarella with the 2015 awards for Most Respected Public Semiconductor Company and for Best Financially Managed Semiconductor Company; both awards are for companies achieving $100M to $500M in annual sales. The awards were presented to Ambarella executives at the GSA annual awards dinner celebration held on Thursday, December 10, 2015 in Santa Clara, California.

How Should Investors React to AMBA Now? Find Out in this Trend Analysis Report